**8. Conclusion**

In recent years, medication formulation into various films has become increasingly popular. The development of innovative polymeric thin films as a drug delivery platform has been pushed by several unwanted problems associated with current dosage forms, such as inconvenient administration, poorer bioavailability, and patient non-compliance. Because of the versatility of this dissolvable film technology platform, it has the potential to be used in a variety of pharmaceutical, biopharmaceutical, and medical sectors in the future. It also allows current pharmaceuticals whose patents are about to expire and will shortly be subject to generic competition to extend their revenue life cycles. In other words, oral films provide product lifetime management. Furthermore, the bulk of the production processes is well-understood and controllable, resulting in a stable and efficient transition from bench to market. The businesses are working to develop a variety of thin films for use in the oral, buccal, sublingual, ophthalmic, and transdermal routes. As a result, polymeric thin films are predicted to stand out as a dosage form as an alternative to traditional dosage forms, overcoming the limits provided by existing dosage forms. Finally, the thin-film technology combined with the chosen medication component must obtain widespread public acceptability, paving the path for other medicines to adopt this portable, extremely handy pharmaceutical form. As new technologies for preparing thin films are quickly launched, the future of film technology appears to be bright.
